NICE Rejects Tecentriq For Small-Cell Lung Cancer In England

Uncertainties Remain Over Long-Term Effectiveness

Roche’s Tecentriq has been rejected by health technology assessment body NICE for use in small-cell lung cancer on the National Health Service. The move follows an earlier knockback for the drug in PD L1-positive triple-negative breast cancer.

Lung cancer
NICE has turned down Tecentriq for small-cell lung cancer • Source: Shutterstock

NICE, the health technology appraisal body for England, has rejected Roche’s Tecentriq (atezolizumab) for small-cell lung cancer, saying there are uncertainties over the duration of the treatment effect and overall survival and that the treatment does not represent a cost-effective use of National Health Service resources.

The recommendation Roche had sought was for routine NHS funding of Tecentriq in combination with carboplatin and etoposide for untreated...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United Kingdom

More from Europe